NCT05077436View on ClinicalTrials.gov

Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

December 29, 2021

Study Completion Date

January 5, 2022

Conditions
Healthy
Interventions
DRUG

Vamifeport Formulation 1

Vamifeport Formulation 1 is available as 60 mg oral capsules

DRUG

Vamifeport Formulation 2

Vamifeport Formulation 2 is available as 60 mg oral capsules

Trial Locations (1)

LS2 9LH

Labcorp Clinical Research Unit Ltd., Leeds

All Listed Sponsors
lead

Vifor (International) Inc.

INDUSTRY

NCT05077436 - Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects | Biotech Hunter | Biotech Hunter